Flexibility and innovation in the FDA’s novel regulatory approval strategies for hematologic drugs

類似資料

• Farrell AT, Goldberg KB, Pazdur R. Flexibility and innovation in the FDA’s novel regulatory approval strategies for hematologic drugs. Blood. 2017;130(11):1285-1289.
  出版事項: (2018)
• Physicians’ Trust in the FDA’s Use of Product-Specific Pathways for Generic Drug Approval
  著者:: Kesselheim, Aaron S., 等
  出版事項: (2016)
• FDA’s ‘Accelerated Approvals’ Are Critical But Raise Thorny Issues
  著者:: Miller, Henry I.
  出版事項: (2019)
• FDA’s New Authority on Drug Shortages
  著者:: Barlas, Stephen
  出版事項: (2012)
• Information to Improve Public Perceptions of the Food and Drug Administration (FDA’s) Tobacco Regulatory Role
  著者:: Amira Osman, 等
  出版事項: (2018-04-01)